PAQR8 promotes breast cancer recurrence and confers resistance to multiple therapies.

ABSTRACT:

Background

Breast cancer mortality is principally due to recurrent disease that becomes resistant to therapy. We recently identified copy number (CN) gain of the putative membrane progesterone receptor PAQR8 as one of four focal CN alterations that preferentially occurred in recurrent metastatic tumors compared to primary tumors in breast cancer patients. Whether PAQR8 plays a functional role in cancer is unknown. Notably, PAQR8 CN gain in recurrent tumors was mutually exclusive with activating ESR1 mutations in patients treated with anti-estrogen therapies and occurred in > 50% of both patients treated with anti-estrogen therapies and those treated with chemotherapy or anti-Her2 agents.

Methods

We used orthotopic mouse models to determine whether PAQR8 overexpression or del

SUBMITTER: Chen S 

PROVIDER: S-EPMC9811758 | biostudies-literature | 2023 Jan

REPOSITORIES: biostudies-literature